Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis (vol 23, pg 596, 2017)

被引：4
|
作者：
Kalincik, T.
Jokubaitis, V
Spelman, T.
机构：
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷 / 14期
关键词：
D O I：
10.1177/1352458517735739
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis
    Kalincik, T.
    Jokubaitis, V.
    Spelman, T.
    Horakova, D.
    Havrdova, E.
    Trojano, M.
    Lechner-Scott, J.
    Lugaresi, A.
    Prat, A.
    Girard, M.
    Duquette, P.
    Grammond, P.
    Solaro, C.
    Grand'Maison, F.
    Hupperts, R.
    Prevost, J.
    Sola, P.
    Ferraro, D.
    Terzi, M.
    Butler, E.
    Slee, M.
    Kermode, A.
    Fabis-Pedrini, M.
    McCombe, P.
    Barnett, M.
    Shaw, C.
    Hodgkinson, S.
    Butzkueven, H.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 596 - 597
  • [2] Cladribine versus fingolimod, natalizumab and interferon for multiple sclerosis
    Kalincik, Tomas
    Jokubaitis, Vilija
    Spelman, Tim
    Horakova, Dana
    Havrdova, Eva
    Trojano, Maria
    Lechner-Scott, Jeannette
    Lugaresi, Alessandra
    Prat, Alexandre
    Girard, Marc
    Duquette, Pierre
    Grammond, Pierre
    Solaro, Claudio
    Grand'Maison, Francois
    Hupperts, Raymond
    Prevost, Julie
    Sola, Patrizia
    Ferraro, Diana
    Terzi, Murat
    Butler, Ernest
    Slee, Mark
    Kermode, Allan
    Fabis-Pedrini, Marzena
    McCombe, Pamela
    Barnett, Michael
    Shaw, Cameron
    Hodgkinson, Suzanne
    Butzkueven, Helmut
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (12) : 1617 - 1626
  • [3] Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis
    Iaffaldano, Pietro
    Lucisano, Giuseppe
    Pozzilli, Carlo
    Morra, Vincenzo Brescia
    Ghezzi, Angelo
    Millefiorini, Enrico
    Patti, Francesco
    Lugaresi, Alessandra
    Zimatore, Giovanni Bosco
    Marrosu, Maria Giovanna
    Amato, Maria Pia
    Bertolotto, Antonio
    Bergamaschi, Roberto
    Granella, Franco
    Coniglio, Gabriella
    Tedeschi, Gioacchino
    Sola, Patrizia
    Lus, Giacomo
    Ferro, Maria Teresa
    Iuliano, Gerardo
    Corea, Francesco
    Protti, Alessandra
    Cavalla, Paola
    Guareschi, Angelica
    Rodegher, Mariaemma
    Paolicelli, Damiano
    Tortorella, Carla
    Lepore, Vito
    Prosperini, Luca
    Sacca, Francesco
    Baroncini, Damiano
    Comi, Giancarlo
    Trojano, Maria
    BRAIN, 2015, 138 : 3275 - 3286
  • [4] Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsingremitting multiple sclerosis
    Roos, Izanne
    Sharmin, Sifat
    Malpas, Charles B.
    Lechner-Scott, Jeannette
    Hodgkinson, Suzanne
    van der Walt, Anneke
    Butzkueven, Helmut
    Buzzard, Katherine
    Skibina, Olga
    Kalincik, Tomas
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (04) : 7 - 8
  • [5] Oral Cladribine and Fingolimod for Relapsing Multiple Sclerosis (vol 362, pg 1738, 2010)
    Li
    Zhang
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (03): : 298 - 298
  • [6] Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis
    Zhu, Chao
    Zhou, Zhen
    Roos, Izanne
    Merlo, Daniel
    Kalincik, Tomas
    Ozakbas, Serkan
    Skibina, Olga
    Kuhle, Jens
    Hodgkinson, Suzanne
    Boz, Cavit
    Alroughani, Raed
    Lechner-Scott, Jeannette
    Barnett, Michael
    Izquierdo, Guillermo
    Prat, Alexandre
    Horakova, Dana
    Havrdova, Eva Kubala
    Macdonell, Richard
    Patti, Francesco
    Khoury, Samia Joseph
    Slee, Mark
    Karabudak, Rana
    Onofrj, Marco
    Van Pesch, Vincent
    Prevost, Julie
    Monif, Mastura
    Jokubaitis, Vilija
    van der Walt, Anneke
    Butzkueven, Helmut
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (12): : 1330 - 1337
  • [7] Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
    Vollmer, Brandi L.
    Nair, Kavita V.
    Sillau, Stefan
    Corboy, John R.
    Vollmer, Timothy
    Alvarez, Enrique
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2019, 6 (02): : 252 - 262
  • [8] Rituximab versus Fingolimod after Natalizumab in Multiple Sclerosis Patients
    Alping, Peter
    Frisell, Thomas
    Novakova, Lenka
    Islam-Jakobsson, Protik
    Salzer, Jonatan
    Bjorck, Anna
    Axelsson, Markus
    Malmestrom, Clas
    Fink, Katharina
    Lycke, Jan
    Svenningsson, Anders
    Piehl, Fredrik
    ANNALS OF NEUROLOGY, 2016, 79 (06) : 950 - 958
  • [9] Multiple Sclerosis Is Natalizumab is effective as Fingolimod?
    Kilger, Ellen
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2016, 84 (05) : 256 - 256
  • [10] Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
    Roos, Izanne
    Sharmin, Sifat
    Malpas, Charles
    Ozakbas, Serkan
    Lechner-Scott, Jeannette
    Hodgkinson, Suzanne
    Alroughani, Raed
    Izquierdo, Guillermo
    Eichau Madueno, Sara
    Boz, Cavit
    van der Walt, Anneke
    Butzkueven, Helmut
    Buzzard, Katherine
    Skibina, Olga
    Foschi, Matteo
    Grand'Maison, Francois
    John, Nevin
    Grammond, Pierre
    Terzi, Murat
    Prevost, Julie
    Barnett, Michael
    Laureys, Guy
    Van Hijfte, Liesbeth
    Luis Sanchez, Jose
    Blanco, Yolanda
    Oh, Jiwon
    Mccombe, Pamela
    Ramo Tello, Cristina
    Soysal, Aysun
    Prat, Alexandre
    Girard, Marc
    Duquette, Pierre
    Yamout, Bassem I.
    Khoury, Samia
    Van Pesch, Vincent
    Macdonell, Richard
    Sa, Maria Jose
    Slee, Mark
    Kuhle, Jens
    Maimone, Davide
    Spitaleri, Daniele L. A.
    Willekens, Barbara
    Al-Asmi, Abdullah
    Robertson, Neil
    Coles, Alasdair
    Brown, J. William L.
    Kalincik, Tomas
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 629 - 631
12345